300 80
Ansor

Portfolio News: Kaleidex makes largest acquisitions to date with expansion into Ireland

Accutool

Founded in 1985, Accutool is a precision engineering business headquartered at a 25,000 sq ft facility in Dublin and a 3,000 sq ft facility in Cork, combining advanced production capability with extensive design and engineering expertise.

Accutool supports highly regulated industries including medical devices and biopharmaceuticals, with capabilities spanning precision CNC machining, design engineering, tooling, machine building, assembly, testing, and fabrication. The business has extensive experience within medical manufacturing, including the production of orthopaedic implant components.

Lisnabrin Engineering

Founded in 2001 by Margaret and Steve Martin, Lisnabrin Engineering is a specialist precision manufacturing business based in Mitchelstown, Co. Cork. Operating from a purpose built 20,000 sq ft facility, Lisnabrin supports customers across the medical device and pharmaceutical industries, providing precision-engineered tooling, prototypes and components.

Its capabilities include CNC machining, Wire EDM, turning, laser welding and marking, electropolishing and metrology. Since its foundation, Lisnabrin has grown from a one-person operation to a team of more than 50.

Gavin Meadows, CEO of Kaleidex, said: “Accutool and Lisnabrin are the largest acquisitions we have made since establishing Kaleidex and represent a major step forward for the group. Both businesses bring deep engineering expertise, strong Irish manufacturing heritage and substantial additional capability into Kaleidex.

“Ireland is strategically very important to us. It is home to one of the world’s strongest concentrations of medical technology businesses, and establishing a meaningful manufacturing presence in Dublin and Cork allows us to be closer, more accessible and more responsive to customers in this market.

“Our ambition is to build Kaleidex into a trusted manufacturing partner to leading medtech businesses. We are doing that by acquiring strong specialist businesses and investing behind them in people, technology, capacity and new manufacturing capability.

“Accutool and Lisnabrin are a significant statement of that intent. We see considerable potential in both businesses and intend to invest further in their teams and manufacturing operations as part of the wider Kaleidex group.”

Gavin McAuliffe, Managing Director of Accutool, said: “Accutool has spent more than 40 years building the engineering knowledge, manufacturing capability and customer relationships that define the business today.

“Joining Kaleidex gives us the opportunity to build on those foundations. Our customers will continue to work with the people and expertise they know at Accutool, while our team will have the backing to invest further in the business and access a broader range of specialist manufacturing capabilities across Kaleidex. We are looking forward to continuing to grow the business from our base here in Ireland.”

Steve Martin, Managing Director of Lisnabrin Engineering, said: “We started Lisnabrin in 2001 with a clear focus on solving complex engineering challenges for our customers. The business has grown substantially since then, but our focus on quality, engineering expertise and responsive customer service has remained constant.

“Becoming part of Kaleidex gives us the opportunity to continue that development with the investment and wider manufacturing capability of the group behind us. We will continue to serve our customers from Mitchelstown with the same team and approach, during the next stage of Lisnabrin’s growth.”

Both Accutool and Lisnabrin will continue to operate from their existing sites in Ireland, retaining their teams, expertise and customer relationships. As part of Kaleidex, the businesses will benefit from continued investment, while customers gain access to an increasingly broad range of specialist medical manufacturing capabilities across the group. The acquisitions extend Kaleidex’s international footprint, adding substantial capacity in Ireland alongside its existing specialist businesses in the United Kingdom and Germany. They also increase the scale of the group as it continues to build a stronger manufacturing platform for leading medtech businesses.

Related articles

How can we help?

Get in Touch

Get in Touch

Please get in touch using the form below.

Close form

Professional Investor Disclaimer

DISCLAIMER

General Notice

RELIANCE ON THIS WEBSITE AND INFORMATION (THE “WEBSITE”) FOR THE PURPOSE OF ENGAGING IN ANY INVESTMENT ACTIVITY MAY EXPOSE AN INDIVIDUAL TO A SIGNIFICANT RISK OF LOSING ALL CAPITAL INVESTED. PLEASE NOTE THAT FOR REGULATORY PURPOSES, BY PROCEEDING WE WILL BE TREATING YOU AS A PROFESSIONAL INVESTOR IN ACCORDANCE WITH THE CLIENT CATEGORISATION RULES AS PRESCRIBED IN THE FCA HANDBOOK.

If you are in any doubt about the action you should take or the contents of this website you should contact your professional advisers authorised under the Financial Services and Markets Act 2000.

This legal and regulatory notice is issued by Ansor LLP. Ansor LLP is authorised and regulated by the Financial Conduct Authority, with Firm Reference Number 1018078. If you do not accept the terms of this disclaimer do not continue to use or access any pages of this Website. Ansor LLP is registered as a limited liability partnership in England and Wales, with registered number OC427505 and its registered office at 50 Hans Crescent, London SW1X 0NA.

 Legal Disclaimer

Ansor LLP provides the Website for the purpose of general information purposes only and the information and materials contained therein should not be relied upon as a substitute for financial or other professional advice. Nothing on this Website constitutes: (i) an offer, advice, invitation or solicitation by Ansor LLP or its affiliates to buy or sell any investments or securities, futures, options or other financial instruments; (ii) an invitation or inducement to engage in investment activity or a financial promotion of any kind; or (iii) investment advice or recommendation. Ansor LLP makes no representation or warranties of any kind with respect to the Website or the information and materials contained therein and disclaims all such representations and warranties including, without limitation, representations or warranties about the accuracy, completeness, or suitability for any purpose of the information and materials published in the Website. Further information may be available on request. Ansor LLP may make changes to the material on the Website at any time without notice and is under no obligation to update the Website nor to notify users of any changes to the Website at any time. Ansor LLP has no obligation to notify a reader or recipient of this publication in the event that any matter, opinion, projection, forecast or estimate contained herein, changes or subsequently becomes inaccurate. Neither Ansor LLP nor any of its directors, employees or other representatives will be liable for loss or damage arising out of or in connection with the use of this Website. This limitation of liability applies to all damages of any kind, including without limitation: compensatory; direct; indirect or consequential damages; loss of data; loss of income or profit; loss of or damages to property; and claims of third parties.

Any reference to “We” within the Website is defined as Ansor LLP acting as investment adviser to Ansor Fund I LP and Ansor IB LP. Investment management services to Ansor Fund I LP and Ansor IB LP are provided by Ansor LLP.

Regulatory Notice and Risks

Please read the information set out below. Potential investors should consult their financial adviser before making any investments. Potential investors should also fully consider the available information, including, but not limited to the risk warnings set out below.Investing entails risks, including possible loss of principal. No representation is being made that any investment or transaction will or is likely to achieve profits or losses similar to those achieved in the past, or that significant losses will be avoided. No assurances or guarantees are given regarding the performance of any investment.

Past performance may not be repeated and should not be seen as a guide to future performance.

The value of investments and the income from them may go down as well as up and investors may not get back the amount originally invested. Any estimates of future performance are based on assumptions that may not be realised. Some investments may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may cause losses. International investing includes risks related to political and economic uncertainties of foreign countries, as well as currency risk. To the extent permitted by applicable law, no liability whatsoever is accepted for any direct or consequential loss, damages, costs or prejudices whatsoever arising from the use of this Website. This Website or any information supplied in connection with this Website by any person is or not to be taken as constituting the giving of investment advice or connection with your proposed investment.
Cookies

A “cookie” is a piece of information that is saved to your PC’s hard disk by the web server. Confirmation of reading and accepting this disclaimer will place a cookie on your PC’s hard disk. This will ease your navigation around this Website by not popping up this disclaimer again during this browser session. This cookie is temporary and will be removed when you close your browser. The cookie is not used for any other reason.

Telephone Recording

Ansor LLP may monitor and record telephone conversations to check and verify instructions, to maintain high quality service standards, to comply with regulatory requirements and for the security of operational and business processes.

Marketing

The distribution of the information on this Website may be restricted by law in certain countries. This Website and the information on it is not addressed to any person resident in the territory or country or jurisdiction where such distribution would be contrary to local law or regulation. Ansor LLP disclaims all responsibility if you access or download any information from this Website in breach of any law or regulation in the country of which you are a citizen or in which you are residing or domiciled.

Conditions of Use

If you have read and understood these conditions of use you may click the “I AGREE” button to proceed. By doing so you acknowledge that you understand the conditions of use and have agreed to abide by them.

By clicking “I AGREE” below this will certify that you have read the above disclaimer and that you understand and agree that:

  • Nothing contained on this Website is deemed to be an offer to buy or sell an investment;
  • You are a professional investor;
  • The value of investments can go down as well as up and there is the possibility of losing all of your investment.
  • Some or all investment services or products may not be available to you in your jurisdiction.